drugset / Trial / NCT04461795
Efficacy of AJOVY (Fremanezumab-vfrm) on Interictal Migraine Related Burden
NaSingle-groupOpen-labelSupportive care
Summary
This study is being conducted to evaluate the efficacy and safety of AJOVY (fremanezumab-vfrm) on interictal migraine related burden in adults.
Timeline
- Start
- 2020-12-01
- Primary completion
- 2022-01-10
- Completion
- 2022-01-10
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Fremanezumab | Monoclonal antibody | 225 mg | Subcutaneous |